Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 366

1.

PK/PD modelling and beyond: impact on drug development.

Breimer DD.

Pharm Res. 2008 Dec;25(12):2720-2. doi: 10.1007/s11095-008-9717-x. Epub 2008 Sep 23.

PMID:
18810328
2.

Pharmacology in The Netherlands: past, present and future.

van Ree JM, Breimer DD.

Trends Pharmacol Sci. 2008 Apr;29(4):167-9. doi: 10.1016/j.tips.2008.01.009. Epub 2008 Mar 19. No abstract available.

PMID:
18355928
3.
4.

P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier.

van der Sandt IC, Gaillard PJ, Voorwinden HH, de Boer AG, Breimer DD.

Pharm Res. 2001 May;18(5):587-92.

PMID:
11465412
5.

Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier.

van der Sandt IC, Smolders R, Nabulsi L, Zuideveld KP, de Boer AG, Breimer DD.

Eur J Pharm Sci. 2001 Aug;14(1):81-6.

PMID:
11457654
6.

Glucocorticoid and type 1 interferon interactions at the blood-brain barrier: relevance for drug therapies for multiple sclerosis.

Gaillard PJ, van Der Meide PH, de Boer AG, Breimer DD.

Neuroreport. 2001 Jul 20;12(10):2189-93.

PMID:
11447332
7.

Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

van der Sandt IC, Vos CM, Nabulsi L, Blom-Roosemalen MC, Voorwinden HH, de Boer AG, Breimer DD.

AIDS. 2001 Mar 9;15(4):483-91.

PMID:
11242145
8.

Future training needs in the pharmaceutical sciences: academia -- industry.

Breimer DD.

Eur J Pharm Sci. 2001 Feb;12(4):347-52.

PMID:
11231100
9.

Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier.

Gaillard PJ, van der Sandt IC, Voorwinden LH, Vu D, Nielsen JL, de Boer AG, Breimer DD.

Pharm Res. 2000 Oct;17(10):1198-205.

PMID:
11145224
10.

Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes.

Gaillard PJ, Voorwinden LH, Nielsen JL, Ivanov A, Atsumi R, Engman H, Ringbom C, de Boer AG, Breimer DD.

Eur J Pharm Sci. 2001 Jan;12(3):215-22.

PMID:
11113640
11.

Methodological issues in microdialysis sampling for pharmacokinetic studies.

de Lange EC, de Boer AG, Breimer DD.

Adv Drug Deliv Rev. 2000 Dec 15;45(2-3):125-48. Review.

PMID:
11108971
12.

Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.

van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD.

Eur J Pharm Sci. 2000 Sep;11(3):207-14.

PMID:
11042226
13.

Microdialysis for pharmacokinetic analysis of drug transport to the brain.

de Lange EC, de Boer BA, Breimer DD.

Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):211-227.

PMID:
10837717
14.

Future challenges for drug delivery research.

Breimer DD.

Adv Drug Deliv Rev. 1998 Sep 7;33(3):265-268. No abstract available.

PMID:
10837666
15.

Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration.

Hesselink MB, Smolders H, De Boer AG, Breimer DD, Danysz W.

Behav Pharmacol. 1999 Feb;10(1):85-98.

PMID:
10780305
16.

A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.

Pereira VA, Auler JO Jr, Carmona MJ, Mateus FH, Lanchote VL, Breimer DD, Santos SR.

Braz J Med Biol Res. 2000 May;33(5):509-14.

18.

Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.

Wijnholds J, deLange EC, Scheffer GL, van den Berg DJ, Mol CA, van der Valk M, Schinkel AH, Scheper RJ, Breimer DD, Borst P.

J Clin Invest. 2000 Feb;105(3):279-85.

19.
20.

Future challenges for drug delivery.

Breimer DD.

J Control Release. 1999 Nov 1;62(1-2):3-6. Review. No abstract available.

PMID:
10518628
21.

Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists.

Hesselink MB, De Boer AG, Breimer DD, Danysz W.

J Neural Transm (Vienna). 1999;106(5-6):409-21.

PMID:
10443547
23.
24.

The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation.

van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF.

J Psychopharmacol. 1999;13(1):10-7.

PMID:
10221355
25.

The transference of results between blood-brain barrier cell culture systems.

de Boer AG, Gaillard PJ, Breimer DD.

Eur J Pharm Sci. 1999 Apr;8(1):1-4. Review. No abstract available.

PMID:
10072472
26.
27.

[Transport of drugs across the blood-brain barrier].

Breimer DD.

Verh K Acad Geneeskd Belg. 1998;60(1):47-60; discussion 60-1. Review. Dutch.

PMID:
9646722
28.

Cytokines and blood-brain barrier permeability.

de Boer AG, Breimer DD.

Prog Brain Res. 1998;115:425-51. Review. No abstract available.

PMID:
9632945
29.

Effect of the Mdr1a P-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice.

Desrayaud S, De Lange EC, Lemaire M, Bruelisauer A, De Boer AG, Breimer DD.

J Pharmacol Exp Ther. 1998 May;285(2):438-43.

30.

Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice.

Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER.

Endocrinology. 1998 Apr;139(4):1789-93.

PMID:
9528963
31.

Transporters and the blood-brain barrier (BBB).

De Boer AB, De Lange EL, Van der Sandt IC, Breimer DD.

Int J Clin Pharmacol Ther. 1998 Jan;36(1):14-5. No abstract available.

PMID:
9476143
32.

Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier.

de Lange EC, Danhof M, de Boer AG, Breimer DD.

Brain Res Brain Res Rev. 1997 Sep 30;25(1):27-49. Review.

PMID:
9370049
33.

Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep.

Tuk B, Oberyé JJ, Pieters MS, Schoemaker RC, Kemp B, van Gerven J, Danhof M, Kamphuisen HA, Cohen AF, Breimer DD, Peck CC.

Clin Pharmacol Ther. 1997 Oct;62(4):444-52.

PMID:
9357396
34.

In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease.

Tanaka E, Breimer DD.

J Clin Pharm Ther. 1997 Aug;22(4):237-49. Review.

PMID:
9548204
35.

Abnormal glutathione conjugation in patients with tyrosinaemia type I.

Mulders TM, Bergman DJ, Poll-The BT, Smit GP, Breimer DD, Mulder GJ, Duran M, Smeitink JA.

J Inherit Metab Dis. 1997 Aug;20(4):473-85.

PMID:
9266383
36.

Partition coefficients (n-octanol/water) of N-butyl-p-aminobenzoate and other local anesthetics measured by reversed-phase high-performance liquid chromatography.

Grouls RJ, Ackerman EW, Korsten HH, Hellebrekers LJ, Breimer DD.

J Chromatogr B Biomed Sci Appl. 1997 Jul 4;694(2):421-5.

PMID:
9252058
37.

The blood-brain barrier in neuroinflammatory diseases.

de Vries HE, Kuiper J, de Boer AG, Van Berkel TJ, Breimer DD.

Pharmacol Rev. 1997 Jun;49(2):143-55. Review. No abstract available.

38.

Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

Breimer DD, Danhof M.

Clin Pharmacokinet. 1997 Apr;32(4):259-67. Review. No abstract available.

PMID:
9113436
39.

Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass.

Auler Júnior JO, Espada EB, Crivelli E, Quintavalle TB, Kurata A, Stolf NA, Issy AM, Paschoa OE, Danhof M, Breimer DD, Chamone DA, Santos SR.

Braz J Med Biol Res. 1997 Mar;30(3):369-74.

PMID:
9246235
40.

Epidural and intrathecal n-butyl-p-aminobenzoate solution in the rat. Comparison with bupivacaine.

Grouls RJ, Meert TF, Korsten HH, Hellebrekers LJ, Breimer DD.

Anesthesiology. 1997 Jan;86(1):181-7.

PMID:
9009953
41.

Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo.

Mathot RA, Wenden EM, Soudijn W, Breimer DD, Ijzerman AP, Danhof M.

J Pharmacol Exp Ther. 1996 Dec;279(3):1439-46.

PMID:
8968369
42.

[Pharmacokinetics as the key to understanding drug actions].

Breimer DD.

Pharm Unserer Zeit. 1996 Jul;25(4):192-3. German. No abstract available.

PMID:
8927632
43.

Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol.

van Steveninck AL, Gieschke R, Schoemaker RC, Roncari G, Tuk B, Pieters MS, Breimer DD, Cohen AF.

Br J Clin Pharmacol. 1996 Jun;41(6):565-73.

44.

Effect of endotoxin on permeability of bovine cerebral endothelial cell layers in vitro.

de Vries HE, Blom-Roosemalen MC, de Boer AG, van Berkel TJ, Breimer DD, Kuiper J.

J Pharmacol Exp Ther. 1996 Jun;277(3):1418-23.

PMID:
8667205
45.

Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo.

Mathoôt RA, Soudijn W, Breimer DD, Ijzerman AP, Danhof M.

Br J Pharmacol. 1996 May;118(2):369-77.

46.

An integrated pharmacokinetic and pharmacodynamic approach to controlled drug delivery.

Breimer DD.

J Drug Target. 1996;3(6):411-5. No abstract available.

PMID:
8863134
47.

Antipyrine, theophylline, and hexobarbital as in vivo P450 probe drugs.

Groen K, Breimer DD.

Methods Enzymol. 1996;272:169-77. No abstract available.

PMID:
8791775
48.

The influence of cytokines on the integrity of the blood-brain barrier in vitro.

de Vries HE, Blom-Roosemalen MC, van Oosten M, de Boer AG, van Berkel TJ, Breimer DD, Kuiper J.

J Neuroimmunol. 1996 Jan;64(1):37-43.

PMID:
8598388
49.

Repeated microdialysis perfusions: periprobe tissue reactions and BBB permeability.

de Lange EC, Danhof M, Zurcher C, de Boer AG, Breimer DD.

Brain Res. 1995 Dec 8;702(1-2):261-5.

PMID:
8846086
50.

Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers.

Mulders TM, Keizer, Ouwerkerk J, van der Velde EA, Breimer DD, Mulder GJ.

Clin Cancer Res. 1995 Dec;1(12):1525-36.

Supplemental Content

Loading ...
Support Center